• Mithridion Inc., of Madison, Wisc., received commitments for $1.25 million in financing. The State of Wisconsin Investment Board, Venture Investors and Rocket Venture Fund are participants in the financing, which will be used to search for additional disease targets for its lead candidate, MCD-386CR, and to find partners for two other compounds in Alzheimer's disease and schizophrenia.

• Rib-X Pharmaceuticals Inc. raised $20 million for development of its antibiotics pipeline. The New Haven, Conn.-based company will begin Phase IIb studies of delafloxacin for resistant infections in early 2011 to validate new objective endpoints for an upcoming Phase III study. It will also choose an initial development candidate for multidrug-resistant Gram-negative bacteria out of its Rx-04 program.